Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment Clinical Trial
Official title:
the Prevalence of Acute Kidney Injury in Patients With Chronic Hepatitis c Virus Receiving Sofuspovir Containing Direct Acting Antiviral Therapy
this study aims is to investigate the occurrence of AKI during antiviral therapy, defined as an increase of 0.3 mg/dL or 50% at least in serum creatinine level when compared with baseline values or more than a 25% reduction in (eGFR) when compared with baseline eGFR in Egyptian patients.In addition to evaluate the change in insulin resistance value after treating patients from HCV.
There are limited published data, currently, suggesting the risk of AKI during oral direct
acting antiviral treatment. Most case reports and retrospective studies reported the presence
of an intrinsic cause of renal injury, with most of the available biopsies showing acute
tubular necrosis (ATN) and acute interstitial nephritis (AIN). Most of these patients had
returned to baseline renal function on cessation of sofosbuvir combination therapy.
Recently it was found that a notable percentage of patients experienced a transient increase
in creatinine during therapy, which could occasionally lead to a more than 50% decrease in
patients' eGFR. Previous studies had also shown that the co-use of nonsteroidal
anti-inflammatory drugs (NSAIDs) and recurrent ascites were at increased risk for AKI during
sofosbuvir-based antiviral therapy.
The primary endpoint of this study is to investigate the occurrence of AKI in Egyptian
patients during antiviral therapy and to highlight its reasons and time of incidence in
addition to the mechanism of this injury.
;